论文部分内容阅读
目的:探讨普罗布考对高血压患者血清血红素氧合酶1(HO-1)水平的影响和意义。方法:筛选40例原发性高血压患者,随机分为两组,分别接受以下药物治疗:苯磺酸左旋氨氯地平2.5mg/d+贝那普利10mg/d(对照组,20例),苯磺酸左旋氨氯地平2.5mg/d+贝那普利10mg/d+普罗布考组500mg/d(实验组,20例);同时入选健康体检者作为健康组(20例),随访4周。采用酶联免疫吸附法(ELISA)测定血清中HO-1的水平,观察比较3组血压、血脂和肝肾功能。结果:实验组和对照组血清HO-1水平明显高于健康组(P<0.05);与对照组相比,实验组TC、LDL-C及HDL-C明显降低(P<0.05);治疗后实验组及对照组血清HO-1水平下降,实验组下降更明显。结论:高血压患者血清HO-1水平显著升高,而普罗布考治疗可以改善高血压患者氧化应激状态,下调其血清HO-1水平,更有助于血压控制。
Objective: To investigate the effect and significance of probucol on the serum level of heme oxygenase 1 (HO-1) in patients with essential hypertension. Methods: Forty patients with essential hypertension were selected and randomly divided into two groups, receiving the following drugs: levamlodipine besylate 2.5 mg / d and benazepril 10 mg / d (control group, n = 20) Levamlodipine besylate 2.5 mg / d + benazepril 10 mg / d + probucol 500 mg / d (experimental group, 20 cases). Healthy subjects were enrolled as healthy group (n = 20) and were followed up for 4 weeks. Serum levels of HO-1 were measured by enzyme-linked immunosorbent assay (ELISA), and blood pressure, blood lipid, liver and kidney function were compared between the three groups. Results: The levels of serum HO-1 in the experimental group and the control group were significantly higher than those in the healthy group (P <0.05). Compared with the control group, the levels of TC, LDL-C and HDL-C in the experimental group were significantly decreased The level of HO-1 in experimental group and control group decreased, and the decrease in experimental group was more obvious. Conclusion: Serum HO-1 levels in patients with hypertension are significantly increased, while probucol treatment can improve the oxidative stress in patients with hypertension, down-regulate serum HO-1 levels, and more conducive to blood pressure control.